However, if in subsequent experiments these results extrapolate to mammalian brain, it would suggest that a therapeutic strategy to decrease tau hyperphosphorylation in AD and other tauopathies may require the simultaneous modulation of several phosphorylation sites. This evidence concerns the gene MAPT and tauopathy.